UNITED THERAPEUTICS CORP (UTHR) Stock Fundamental Analysis
USA - NASDAQ:UTHR - US91307C1027 - Common Stock
440 USD
-5.38 (-1.21%)
440 USD
0 (0%)
UTHR gets a fundamental rating of 7 out of 10. The analysis compared the fundamentals against 536 industry peers in the Biotechnology industry. UTHR has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. UTHR may be a bit undervalued, certainly considering the very reasonable score on growth These ratings could make UTHR a good candidate for value and quality investing.
1. Profitability
1.1 Basic Checks
In the past year UTHR was profitable.
In the past year UTHR had a positive cash flow from operations.
In the past 5 years UTHR has always been profitable.
Each year in the past 5 years UTHR had a positive operating cash flow.
1.2 Ratios
The Return On Assets of UTHR (15.71%) is better than 96.09% of its industry peers.
UTHR has a better Return On Equity (17.31%) than 95.16% of its industry peers.
UTHR has a Return On Invested Capital of 16.17%. This is amongst the best in the industry. UTHR outperforms 96.46% of its industry peers.
The Average Return On Invested Capital over the past 3 years for UTHR is in line with the industry average of 15.49%.
The 3 year average ROIC (14.96%) for UTHR is below the current ROIC(16.17%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 15.71% | ||
| ROE | 17.31% | ||
| ROIC | 16.17% |
ROA(3y)14%
ROA(5y)12.47%
ROE(3y)16.72%
ROE(5y)15.47%
ROIC(3y)14.96%
ROIC(5y)13.31%
1.3 Margins
UTHR's Profit Margin of 40.36% is amongst the best of the industry. UTHR outperforms 97.95% of its industry peers.
In the last couple of years the Profit Margin of UTHR has grown nicely.
The Operating Margin of UTHR (50.06%) is better than 99.63% of its industry peers.
UTHR's Operating Margin has improved in the last couple of years.
UTHR has a better Gross Margin (88.98%) than 90.32% of its industry peers.
UTHR's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 50.06% | ||
| PM (TTM) | 40.36% | ||
| GM | 88.98% |
OM growth 3Y7.2%
OM growth 5Y2.85%
PM growth 3Y13.74%
PM growth 5YN/A
GM growth 3Y-1.27%
GM growth 5Y-0.58%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so UTHR is still creating some value.
The number of shares outstanding for UTHR has been reduced compared to 1 year ago.
The number of shares outstanding for UTHR has been increased compared to 5 years ago.
Compared to 1 year ago, UTHR has an improved debt to assets ratio.
2.2 Solvency
An Altman-Z score of 19.18 indicates that UTHR is not in any danger for bankruptcy at the moment.
UTHR has a Altman-Z score of 19.18. This is amongst the best in the industry. UTHR outperforms 90.50% of its industry peers.
There is no outstanding debt for UTHR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 19.18 |
ROIC/WACC1.7
WACC9.5%
2.3 Liquidity
UTHR has a Current Ratio of 7.26. This indicates that UTHR is financially healthy and has no problem in meeting its short term obligations.
UTHR's Current ratio of 7.26 is fine compared to the rest of the industry. UTHR outperforms 70.20% of its industry peers.
A Quick Ratio of 6.94 indicates that UTHR has no problem at all paying its short term obligations.
UTHR's Quick ratio of 6.94 is fine compared to the rest of the industry. UTHR outperforms 68.90% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.26 | ||
| Quick Ratio | 6.94 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 17.74% over the past year.
The Earnings Per Share has been growing by 16.88% on average over the past years. This is quite good.
UTHR shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 17.62%.
UTHR shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 14.71% yearly.
EPS 1Y (TTM)17.74%
EPS 3Y34.86%
EPS 5Y16.88%
EPS Q2Q%9.57%
Revenue 1Y (TTM)17.62%
Revenue growth 3Y19.52%
Revenue growth 5Y14.71%
Sales Q2Q%11.71%
3.2 Future
Based on estimates for the next years, UTHR will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.54% on average per year.
Based on estimates for the next years, UTHR will show a quite strong growth in Revenue. The Revenue will grow by 10.10% on average per year.
EPS Next Y14.09%
EPS Next 2Y8.76%
EPS Next 3Y5.24%
EPS Next 5Y13.54%
Revenue Next Year11.6%
Revenue Next 2Y8.62%
Revenue Next 3Y7.44%
Revenue Next 5Y10.1%
3.3 Evolution
The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 17.17 indicates a rather expensive valuation of UTHR.
Based on the Price/Earnings ratio, UTHR is valued cheaper than 95.72% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 27.02. UTHR is valued slightly cheaper when compared to this.
UTHR is valuated correctly with a Price/Forward Earnings ratio of 15.12.
94.97% of the companies in the same industry are more expensive than UTHR, based on the Price/Forward Earnings ratio.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.57, UTHR is valued a bit cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 17.17 | ||
| Fwd PE | 15.12 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, UTHR is valued cheaply inside the industry as 96.65% of the companies are valued more expensively.
Based on the Price/Free Cash Flow ratio, UTHR is valued cheaply inside the industry as 95.16% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 18.58 | ||
| EV/EBITDA | 9.5 |
4.3 Compensation for Growth
UTHR's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
The excellent profitability rating of UTHR may justify a higher PE ratio.
PEG (NY)1.22
PEG (5Y)1.02
EPS Next 2Y8.76%
EPS Next 3Y5.24%
5. Dividend
5.1 Amount
UTHR does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
440
-5.38 (-1.21%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners99.47%
Inst Owner Change-0.11%
Ins Owners1.76%
Ins Owner Change4.02%
Market Cap19.90B
Analysts80.91
Price Target489.79 (11.32%)
Short Float %6.27%
Short Ratio3.33
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-4.95%
Min EPS beat(2)-9.46%
Max EPS beat(2)-0.45%
EPS beat(4)0
Avg EPS beat(4)-4.06%
Min EPS beat(4)-9.46%
Max EPS beat(4)-0.45%
EPS beat(8)3
Avg EPS beat(8)-1.6%
EPS beat(12)6
Avg EPS beat(12)-0.99%
EPS beat(16)7
Avg EPS beat(16)-3.25%
Revenue beat(2)1
Avg Revenue beat(2)2.03%
Min Revenue beat(2)-2.65%
Max Revenue beat(2)6.71%
Revenue beat(4)2
Avg Revenue beat(4)0.97%
Min Revenue beat(4)-2.65%
Max Revenue beat(4)6.71%
Revenue beat(8)6
Avg Revenue beat(8)2.26%
Revenue beat(12)8
Avg Revenue beat(12)1.8%
Revenue beat(16)10
Avg Revenue beat(16)1.71%
PT rev (1m)26.72%
PT rev (3m)24.8%
EPS NQ rev (1m)-0.46%
EPS NQ rev (3m)-1.79%
EPS NY rev (1m)1.31%
EPS NY rev (3m)-1.79%
Revenue NQ rev (1m)-0.26%
Revenue NQ rev (3m)-2.6%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.76%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 17.17 | ||
| Fwd PE | 15.12 | ||
| P/S | 6.47 | ||
| P/FCF | 18.58 | ||
| P/OCF | 14.51 | ||
| P/B | 2.77 | ||
| P/tB | 2.82 | ||
| EV/EBITDA | 9.5 |
EPS(TTM)25.62
EY5.82%
EPS(NY)29.1
Fwd EY6.61%
FCF(TTM)23.68
FCFY5.38%
OCF(TTM)30.32
OCFY6.89%
SpS68.05
BVpS158.6
TBVpS156.14
PEG (NY)1.22
PEG (5Y)1.02
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 15.71% | ||
| ROE | 17.31% | ||
| ROCE | 20.88% | ||
| ROIC | 16.17% | ||
| ROICexc | 27.55% | ||
| ROICexgc | 28.28% | ||
| OM | 50.06% | ||
| PM (TTM) | 40.36% | ||
| GM | 88.98% | ||
| FCFM | 34.8% |
ROA(3y)14%
ROA(5y)12.47%
ROE(3y)16.72%
ROE(5y)15.47%
ROIC(3y)14.96%
ROIC(5y)13.31%
ROICexc(3y)29.18%
ROICexc(5y)24.89%
ROICexgc(3y)30.03%
ROICexgc(5y)25.71%
ROCE(3y)19.31%
ROCE(5y)17.18%
ROICexcg growth 3Y23.22%
ROICexcg growth 5Y4.92%
ROICexc growth 3Y22.46%
ROICexc growth 5Y5.97%
OM growth 3Y7.2%
OM growth 5Y2.85%
PM growth 3Y13.74%
PM growth 5YN/A
GM growth 3Y-1.27%
GM growth 5Y-0.58%
F-Score6
Asset Turnover0.39
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 376.79% | ||
| Cap/Sales | 9.76% | ||
| Interest Coverage | 58.37 | ||
| Cash Conversion | 84.62% | ||
| Profit Quality | 86.22% | ||
| Current Ratio | 7.26 | ||
| Quick Ratio | 6.94 | ||
| Altman-Z | 19.18 |
F-Score6
WACC9.5%
ROIC/WACC1.7
Cap/Depr(3y)347.88%
Cap/Depr(5y)280.91%
Cap/Sales(3y)8.54%
Cap/Sales(5y)7.36%
Profit Quality(3y)85.86%
Profit Quality(5y)98.64%
High Growth Momentum
Growth
EPS 1Y (TTM)17.74%
EPS 3Y34.86%
EPS 5Y16.88%
EPS Q2Q%9.57%
EPS Next Y14.09%
EPS Next 2Y8.76%
EPS Next 3Y5.24%
EPS Next 5Y13.54%
Revenue 1Y (TTM)17.62%
Revenue growth 3Y19.52%
Revenue growth 5Y14.71%
Sales Q2Q%11.71%
Revenue Next Year11.6%
Revenue Next 2Y8.62%
Revenue Next 3Y7.44%
Revenue Next 5Y10.1%
EBIT growth 1Y21.63%
EBIT growth 3Y28.12%
EBIT growth 5Y17.97%
EBIT Next Year18.1%
EBIT Next 3Y5.05%
EBIT Next 5Y-4.6%
FCF growth 1Y59%
FCF growth 3Y31.3%
FCF growth 5YN/A
OCF growth 1Y58%
OCF growth 3Y30.42%
OCF growth 5YN/A